Entity

Time filter

Source Type


Romeo M.,Institute Catala dOncologia Badalona | Romeo M.,Institute Catala dOncologia lHospitalet | Pons F.,Hospital del Mar Parc de Salut Mar | Barretina P.,Institute Catala dOncologia Girona | And 2 more authors.
World Journal of Surgical Oncology | Year: 2013

Background: Borderline ovarian tumors (BOTs) are a subset of epithelial ovarian tumors with low malignant potential but significant risk of relapse (10% to 30%). Unfortunately, surgical prognostic factors for BOT relapse have not been clearly identified, probably due to the use of heterogeneous surgical definitions and limited follow-up. The aim of this study was to assess potential relapse risk factors using standard surgical definitions and long follow-up.Methods: All patients diagnosed with BOT for a period of more than 10 years in a single institution were included in the analysis. Complete surgical staging was defined as the set of procedures that follow standard guidelines for staging surgery (except lymphadenectomy), performed either with one or two interventions. Fertility-sparing surgeries that preserved one ovary and the uterus but included all the remaining procedures were classified as complete staging. The relationship between potential risk factors and time to BOT relapse was assessed by log-rank tests corrected for multiple comparisons and Cox regression.Results: Forty-six patients with a median follow-up of 5.4 years were included, of whom 91.3% had been diagnosed as FIGO stage I disease and 45.7% had received complete staging surgery. Five relapses were detected (10.9%), all of them in women who had been diagnosed with stage I disease and had received incomplete staging surgery. Log-rank tests confirmed the association between incomplete staging surgery and shorter time to BOT relapse.Conclusions: Complete staging surgery should be considered a cornerstone of BOT treatment in order to minimize the risk of relapse. © 2013 Romeo et al.; licensee BioMed Central Ltd. Source


Garcia Del Muro Solans X.,Institute Catala dOncologia lHospitalet | Martin Broto J.,Hospital Son Espases | Lianes Barragan P.,Hospital de Mataro | Cubedo Cervera R.,Hospital Puerta de Hierro
Clinical and Translational Oncology | Year: 2012

Soft tissue sarcomas are uncommon tumors of mesenchimal cell origin. Criteria for suspicion is a soft tissue mass that is increasing in size, and has a size greater than 5 cm or is located under the deep fascia. Diagnosis and management of these patients should preferably be performed by a specialist multidisciplinary team in a referral center. Assessment of a patient with a suspect of sarcoma should include magnetic resonance and biopsy performed prior to surgery. Primary local therapy for patients with localized sarcoma is based on wide surgical resection with a tumor-free tissue margin, in association in most cases with radiotherapy. Adjuvant chemotherapy constitutes an option that could be considered in high-risk sarcomas of the extremities. When metastasis are present, surgery of pulmonary lesions, in some selected patients, and chemotherapy are current available options. Source


Bellmunt J.,Harvard University | Puente J.,Hospital Clinico San Carlos | Garcia de Muro J.,Institute Catala dOncologia lHospitalet | Lainez N.,Complejo Hospitalario de Navarra | And 2 more authors.
Clinical and Translational Oncology | Year: 2014

The purpose of this article was to provide updated recommendations for the diagnosis and treatment of renal cell carcinoma. Pathological confirmation is mandatory before treatment with ablative or focal therapies before any type of systemic therapy. Renal cell cancer should be staged according to the TNM classification system. A laparoscopic nephron-sparing surgery should be the approach for tumors <4 cm if technically feasible. Otherwise, radical (or partial in selected cases) nephrectomy is the treatment of choice, with lymph node dissection only performed in patients with clinically detected lymph node involvement. Some retrospective evidence for a cytoreductive nephrectomy in the postimmunotherapy era suggests a benefit in patients with good or intermediate risk or for patients with a symptomatic primary lesion. Adjuvant treatment with chemotherapy or with targeted agents is not recommended and studies are ongoing today. Patients with metastatic disease should be staged by computed tomography scans of the chest, abdomen and pelvis. The efficacy of sunitinib, bevacizumab plus interferon-α, and pazopanib is well established in patients with good and intermediate risk as well for temsirolimus in poor-risk patients. These four agents are considered standard of care in first-line treatment. Sorafenib, axitinib and everolimus are standard of care in second line in different settings based on their benefit in PFS. Besides some benefit described for IL-2 in highly selected patients in first line, there is a promising and emerging role for the new immunotherapeutic approaches in metastatic renal cell carcinoma. © 2014, The Author(s). Source


Mesia R.,Institute Catala dOncologia lHospitalet | Pastor M.,Hospital General Universitario la Fe | Grau J.J.,Servicio de Oncologia Medica | Del Barco E.,Hospital Universitario Of Salamanca
Clinical and Translational Oncology | Year: 2013

Nasopharyngeal carcinoma cases are not frequently encountered in our environment. Local stages are treated with radiotherapy. For advanced local stages, the association of chemotherapy with radiotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum-based chemotherapy and patients may achieve a long survival time. © 2013 Federación de Sociedades Españolas de Oncología (FESEO). Source


Garcia Del Muro X.,Institute Catala dOncologia lHospitalet | Gallardo E.,Hospital Parc Tauli | Garcia Carbonero I.,Hospital Virgen de la Salud | Lainez N.,Hospital de Navarra | And 10 more authors.
Cancer Chemotherapy and Pharmacology | Year: 2014

Clear-cell renal cell carcinoma (RCC) is the most common kidney cancer. New treatment options of localized RCC recently incorporated include laparoscopic surgery, nephron-sparing surgery, ablative techniques and active surveillance. But 50 % of patients may develop disease recurrence attributable to subclinical metastases. In these cases, and considering the low benefits of chemotherapy, new targeted therapies such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors have been developed as first- and second-line treatment. Both sunitinib and pazopanib are TKIs that constitute the first-line treatment option in patients with metastatic RCC. As second-line treatment, sequential therapy with a second TKI or a mTOR inhibitor is recommended. This review has collected together a series of recommendations issued by the Spanish Oncology Genitourinary Group with the aim of facilitating the treatment of these patients. Each recommendation is accompanied by the level of evidence and grade of recommendation on the basis of the available data. © 2014 Springer-Verlag. Source

Discover hidden collaborations